Victoza (liraglutide) Injection, for Subcutaneous Use

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) April 2016 ADVERSE REACTIONS Inclusion of results from Trial NN2211-3916, which was a 26-week double-blind placebo-controlled,...
Source: Drugs.com - Labeling Changes - Category: Drugs & Pharmacology Source Type: alerts